Fixed-dose nivolumab plus relatlimab-rmbw (Opdualag) elicited continued progression-free survival (PFS) benefit vs nivolumab (Opdivo) alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial (NCT03470922) that were presented at the 2022 ASCO Annual Meeting.
Archive | Melanoma News
Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma
Posted in Melanoma News, Health Professionals, Of Interest
Iovance Biotherapeutics Releases Positive Clinical Data for Lifileucel in Advanced Melanoma
Analysis included a 29% objective response rate in cohort 4 of the C-144-01 study, the company says.
Posted in Melanoma News, Health Professionals, Clinical Trials
New research confirms some melanomas may be harmless – but which ones?
Examine, a weekly newsletter covering the latest developments in science, is sent every Tuesday. Below is an excerpt – sign up to get the whole newsletter in your inbox.
Posted in Melanoma News, Patients, Latest News
Veterans at Higher Risk of Deadly Skin Cancers
TUESDAY, June 7, 2022 (HealthDay News) — U.S. veterans are at higher risk for melanoma, the deadliest form of skin cancer, than most Americans, and new research finds they are also more likely to have advanced-stage disease when it’s detected.
Posted in Melanoma News, Patients, Latest News
 |
 |
 |
 |
